The first patient in a Phase 1/2 clinical trial (“the Alta trial”) designed to assess safety and tolerability of SB-525 gene therapy has received treatment. Sangamo Therapeutics, in a collaboration with Pfizer, is developing the SB-525 gene therapy to correct the Factor VIII (FVIII) defect in hemophilia A patients.
The Alta trial (NCT03061201) is currently recruiting up to 20 male patients with severe hemophilia A, as evidenced by a circulating FVIII activity that is less than 1% of normal. This dose-ranging study, taking place in Seattle and Duarte, California, will assess SB-525 adverse events and the levels of circulating FVIII for up to three years after a single SB-525 infusion.
Hemophilia A patients need to repeatedly receive FVIII blood infusions to replace defects in blood clotting Factor VIII and prevent bleeding. Now, a single SB-525 administration may enable patient’s own cells to constantly produce the same amino acid sequence used in replacement therapy (Refacto and Xyntha).
SB-525 relies on a genetically engineered virus, recombinant adeno-associated virus (rAAV), carrying a “healthy” FVIII gene construct. The rAAV is harmless for humans, and it delivers the corrected gene to cells in tissues. SB-525 rAAV is designed to restrict FVIII gene expression to the liver, a strategy intended to increase FVIII long-term hepatic production in hemophilia A patients.
This potential therapy results from a global collaboration and license agreement between Sangamo and Pfizer to develop and commercialize gene therapies for hemophilia. “We are excited to see progress in our partnership program for SB-525 with Sangamo,” said Greg LaRosa, chief scientific officer, Pfizer Rare Disease, in a press release issued by Sangamo. “[W]e are advancing the promise of gene therapy with the hope of making a meaningful impact for people living with Hemophilia A.”
Earlier this year, the U.S. Food and Drug Administration granted Orphan Drug and Fast Track designations to SB-525, which also received Orphan Medicinal Product designation from the European Medicines Agency.
Sangamo is also conducting a Phase 1 trial (NCT02695160) of a gene therapy, SB-FIX, in males with severe hemophilia B. This study is currently recruiting up to 12 patients at sites in California and Michigan, and more information is available on its clinical trials.gov webpage.
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?